APLT News and Press, Applied Therapeutics Inc. From 08/12/25

2025-08-12 18:45:13 ET Applied Therapeutics, Inc. (APLT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 1.88%. The average open to low on the day of earnings was -8.21%. The average ope...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Applied Therapeutics Inc. (APLT) is expected to report $-0.17 for Q2 2025

Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmac...

2025-05-19 14:30:46 ET Applied Therapeutics Drops 19% Despite New Data Presentation Applied Therapeutics Inc. ( APLT ) fell 19.12%, pulling down the PRISM Emerging Pharmaceuticals Index , after releasing 12- and 24-month clinical data from its INSPIRE Phase 2/3 trial for gov...

S lowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 ...

2025-05-13 17:56:08 ET More on Applied Therapeutics Seeking Alpha’s Quant Rating on Applied Therapeutics Historical earnings data for Applied Therapeutics Financial information for Applied Therapeutics Read the full article on Seeking Alpha For...

- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosem...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that it will present full 12-month clinical results fro...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...